$10.75
-0.32-2.89%
At Close: -
$10.75
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Regenxbio
RGNXNASDAQ
Regenxbio (NASDAQ:RGNX) Stock, Analyst Ratings, Price Targets, Predictions
Regenxbio Inc has a consensus price target of $41.13, established from looking at the 46 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Goldman Sachs, and HC Wainwright & Co. on June 20, 2024, June 7, 2024, and May 15, 2024. With an average price target of $38 between HC Wainwright & Co., Goldman Sachs, and HC Wainwright & Co., there's an implied 253.49% upside for Regenxbio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Goldman Sachs
Stifel
RBC Capital
Chardan Capital
1calculated from analyst ratings
Analyst Ratings for Regenxbio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/20/2024 | Buy Now | 253.49% | HC Wainwright & Co. | Yi Chen | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2024 | Buy Now | 253.49% | Goldman Sachs | Paul Choi | → $38 | Initiates | → Buy | Get Alert |
| 05/15/2024 | Buy Now | 253.49% | HC Wainwright & Co. | Yi Chen | $36 → $38 | Maintains | Buy | Get Alert |
| 04/12/2024 | Buy Now | 272.09% | Stifel | Annabel Samimy | → $40 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 234.88% | HC Wainwright & Co. | Yi Chen | → $36 | Initiates | → Buy | Get Alert |
| 03/08/2024 | Buy Now | 225.58% | RBC Capital | Luca Issi | $20 → $35 | Upgrade | Sector Perform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 383.72% | Chardan Capital | Daniil Gataulin | $52 → $52 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | 411.63% | Barclays | Gena Wang | $45 → $55 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | — | Leerink Partners | Mani Foroohar | — | Upgrade | Market Perform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 262.79% | Baird | Brian Skorney | $34 → $39 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 95.35% | Wedbush | Andreas Argyrides | → $21 | Reiterates | Neutral → Neutral | Get Alert |
| 02/21/2024 | Buy Now | 318.6% | Raymond James | Dane Leone | → $45 | Reinstates | → Outperform | Get Alert |
| 02/12/2024 | Buy Now | 95.35% | Wedbush | Andreas Argyrides | → $21 | Reiterates | Neutral → Neutral | Get Alert |
| 11/01/2023 | Buy Now | 225.58% | Stifel | Annabel Samimy | → $35 | Initiates | → Buy | Get Alert |
| 10/05/2023 | Buy Now | 86.05% | Wedbush | Andreas Argyrides | → $20 | Reiterates | Neutral → Neutral | Get Alert |
| 10/04/2023 | Buy Now | 86.05% | RBC Capital | Luca Issi | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/29/2023 | Buy Now | 290.7% | Morgan Stanley | Vikram Purohit | $43 → $42 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | 411.63% | Chardan Capital | Daniil Gataulin | → $55 | Reiterates | → Buy | Get Alert |
| 07/12/2023 | Buy Now | 86.05% | RBC Capital | Luca Issi | → $20 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 06/20/2023 | Buy Now | 290.7% | Baird | Brian Skorney | → $42 | Initiates | → Outperform | Get Alert |
| 06/02/2023 | Buy Now | 290.7% | Baird | Brian Skorney | → $42 | Initiates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 300% | Morgan Stanley | Vikram Purohit | $46 → $43 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 411.63% | Chardan Capital | Daniil Gataulin | $61 → $55 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 86.05% | RBC Capital | Luca Issi | $22 → $20 | Maintains | Sector Perform | Get Alert |
| 03/06/2023 | Buy Now | 327.91% | Morgan Stanley | Vikram Purohit | $50 → $46 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 467.44% | Chardan Capital | Daniil Gataulin | → $61 | Reiterates | → Buy | Get Alert |
| 01/23/2023 | Buy Now | 30.23% | SVB Leerink | Mani Foroohar | $15 → $14 | Maintains | Market Perform | Get Alert |
| 11/21/2022 | Buy Now | 365.12% | Morgan Stanley | Vikram Purohit | $52 → $50 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 467.44% | Chardan Capital | Daniil Gataulin | $70 → $61 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 30.23% | SVB Leerink | Mani Foroohar | $13 → $14 | Maintains | Market Perform | Get Alert |
| 10/04/2022 | Buy Now | 169.77% | RBC Capital | Luca Issi | $47 → $29 | Maintains | Sector Perform | Get Alert |
| 09/09/2022 | Buy Now | 383.72% | Morgan Stanley | Vikram Purohit | $46 → $52 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 327.91% | Morgan Stanley | Vikram Purohit | $47 → $46 | Maintains | Overweight | Get Alert |
| 06/23/2022 | Buy Now | 467.44% | Berenberg | Caroline Palomeque | → $61 | Initiates | → Buy | Get Alert |
| 06/23/2022 | Buy Now | 337.21% | UBS | Eliana Merle | $51 → $47 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 337.21% | Morgan Stanley | Vikram Purohit | $51 → $47 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | 551.16% | Chardan Capital | Daniil Gataulin | $76 → $70 | Maintains | Buy | Get Alert |
| 03/23/2022 | Buy Now | 374.42% | Morgan Stanley | Vikram Purohit | $50 → $51 | Maintains | Overweight | Get Alert |
| 03/02/2022 | Buy Now | 132.56% | SVB Leerink | Mani Foroohar | $29 → $25 | Maintains | Market Perform | Get Alert |
| 02/10/2022 | Buy Now | 169.77% | SVB Leerink | Mani Foroohar | $35 → $29 | Maintains | Market Perform | Get Alert |
| 01/28/2022 | Buy Now | 225.58% | SVB Leerink | Mani Foroohar | $43 → $35 | Maintains | Market Perform | Get Alert |
| 12/15/2021 | Buy Now | 169.77% | Wedbush | Andreas Argyrides | — | Initiates | → Neutral | Get Alert |
| 11/03/2021 | Buy Now | 737.21% | Chardan Capital | Geulah Livshits | — | Maintains | Buy | Get Alert |
| 11/03/2021 | Buy Now | 300% | SVB Leerink | Mani Foroohar | — | Maintains | Market Perform | Get Alert |
| 09/14/2021 | Buy Now | 411.63% | RBC Capital | Luca Issi | — | Maintains | Sector Perform | Get Alert |
| 09/14/2021 | Buy Now | 662.79% | Barclays | Gena Wang | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Regenxbio (RGNX) stock?
The latest price target for Regenxbio (NASDAQ:RGNX) was reported by HC Wainwright & Co. on June 20, 2024. The analyst firm set a price target for $38.00 expecting RGNX to rise to within 12 months (a possible 253.49% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regenxbio (RGNX)?
The latest analyst rating for Regenxbio (NASDAQ:RGNX) was provided by HC Wainwright & Co., and Regenxbio reiterated their buy rating.
When was the last upgrade for Regenxbio (RGNX)?
The last upgrade for Regenxbio Inc happened on March 8, 2024 when RBC Capital raised their price target to $35. RBC Capital previously had a sector perform for Regenxbio Inc.
When was the last downgrade for Regenxbio (RGNX)?
There is no last downgrade for Regenxbio.
When is the next analyst rating going to be posted or updated for Regenxbio (RGNX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regenxbio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regenxbio was filed on June 20, 2024 so you should expect the next rating to be made available sometime around June 20, 2025.
Is the Analyst Rating Regenxbio (RGNX) correct?
While ratings are subjective and will change, the latest Regenxbio (RGNX) rating was a reiterated with a price target of $38.00 to $38.00. The current price Regenxbio (RGNX) is trading at is $10.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.